Isabele Avila Small

Isabele Avila Small

Auto-generated profile, based on publicly available information

Isabele Avila Small

Data Management and Analysis, Instituto Nacional de Cancer, Rio de Janeiro, BRAZIL

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MZMauro Zukin
Mauro Zukin
CBCarlos H. Barrios
Carlos H. Barrios
JPJose Rodrigues Pereira
Jose Rodrigues Pereira
RRRonaldo De Albuquerque Ribeiro
Ronaldo De Albuquerque Ribeiro
CBCarlos Augusto de Mendonça Beato
Carlos Augusto de Mendonça Beato
RLRogerio C. Lilenbaum
Rogerio C. Lilenbaum
Purpose: To compare single-agent pemetrexed (P) versus the combination of carboplatin and pemetrexed (CP) in first-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. Patients and Methods: In a multicenter phase III randomized trial, patients with advanced NSCLC, ECOG PS of 2, any histology at first and later amended to nonsquamous only, no prior chemotherapy, and adequate organ function were randomly assigned to P alone (500 mg/m2) or CP (area under the curve of 5 and 500 mg/m2, respectively) administered every 3 weeks for a total of four cycles. The primary end point was overall survival (OS). Results: A total of 205 eligible patients were enrolled from eight centers in Brazil and one in the United States from April 2008 to July 2011. The response rates were 10.3% for P and 23.8% for CP (P = .032). In the intent-to-treat population, the median PFS was 2.8 months for P and 5.8 months for CP (hazard ratio [HR], 0.46; 95% CI, 0.35 to 0.63; P < .001), and the median OS was 5.3 months for P and 9.3 months for CP (HR, 0.62; 95% CI, 0.46 to 0.83; P = .001). One-year survival rates were 21.9% and 40.1%, respectively. Similar results were seen when patients with squamous disease were excluded from the analysis. Anemia (grade 3, 3.9%; grade 4, 11.7%) and neutropenia (grade 3, 1%; grade 4, 6.8%) were more frequent with CP. There were four treatment-related deaths in the CP arm. Conclusion: Combination chemotherapy with CP significantly improves survival in patients with advanced NSCLC and ECOG PS of 2.

1 November 2013 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
HAHeliton S. Antunes
Heliton S. Antunes
DHDaniel Herchenhorn
Daniel Herchenhorn
ISIsabele A. Small
Isabele A. Small
CACarlos M.M. Araújo
Carlos M.M. Araújo
CVCelia Maria Pais Viégas
Celia Maria Pais Viégas
CFCarlos G. Ferreira
Carlos G. Ferreira

19 October 2006 in Blood
Verified
Journal Article
Open access
PDF file
HAHéliton Spíndola Antunes
Héliton Spíndola Antunes
AAAlexandre Mello de Azevedo
Alexandre Mello de Azevedo
LBLuiz Fernando da Silva Bouzas
Luiz Fernando da Silva Bouzas
CACarlos Alberto Esteves Adão
Carlos Alberto Esteves Adão
CPClaudia Tereza Pinheiro
Claudia Tereza Pinheiro
CFCarlos Gil Ferreira
Carlos Gil Ferreira
We investigated the clinical effects of low-power laser therapy (LPLT) on prevention and reduction of severity of conditioning-induced oral mucositis (OM) for hematopoietic stem cell transplantation (HSCT). We randomized 38 patients who underwent autologous (AT) or allogeneic (AL) HSCT. A diode InGaAlP was used, emitting light at 660 nm, 50 mW, and 4 J/cm2, measured at the fiberoptic end with 0.196 cm2 of section area. The evaluation of OM was done using the Oral Mucositis Assessment Scale (OMAS) and the World Health Organization (WHO) scale. In the LPLT group, 94.7% of patients had an OM grade (WHO) lower than or equal to grade 2, including 63.2% with grade 0 and 1, whereas in the controls group, 31.5% of patients had an OM grade lower than or equal to grade 2 (P < .001). Remarkably, the hazard ratio (HR) for grades 2, 3, and 4 OM was 0.41 (range, 0.22-0.75; P = .002) and for grades 3 and 4 it was 0.07 (range, 0.11-0.53; P < .001). Using OMAS by the calculation of ulcerous area, 5.3% of the laser group presented with ulcers of 9.1 cm2 to 18 cm2, whereas 73.6% of the control group presented with ulcers from 9.1 cm2 to 18 cm2 (P = .003). Our results indicate that the use of upfront LPLT in patients who have undergone HSCT is a powerful instrument in reducing the incidence of OM and is now standard in our center.

1 August 2017 in Oral Oncology
Verified
Journal Article
Closed access
HAHéliton S. Antunes
Héliton S. Antunes
DHDaniel Herchenhorn
Daniel Herchenhorn
ISIsabele A. Small
Isabele A. Small
CACarlos M.M. Araújo
Carlos M.M. Araújo
CVCelia Maria Pais Viégas
Celia Maria Pais Viégas
CFCarlos G. Ferreira
Carlos G. Ferreira

10 March 2014 in Cancer
Verified
Journal Article
Open access
PDF file
ARAngelica Nogueira Rodrigues
Angelica Nogueira Rodrigues
GMGiulliana Moralez
Giulliana Moralez
RGRachele Grazziotin
Rachele Grazziotin
CCClaudio C. Carmo
Claudio C. Carmo
ISIsabele A. Small
Isabele A. Small
CFCarlos G. Ferreira
Carlos G. Ferreira
BACKGROUND: Cisplatin‐based chemoradiation (CRT) is the standard treatment for patients with locally advanced cervical cancer. Epidermal growth factor receptor (EGFR) is frequently overexpressed in cervical cancer, and EGFR inhibition itself has antitumor effects and potentiates CRT. Results of a previous phase 1 trial of the EGFR inhibitor erlotinib combined with cisplatin‐based CRT (E + CRT) recommended a phase 2 erlotinib dose of 150 mg/day.METHODS: Eligibility criteria included International Federation of Gynecology and Obstetrics stage IIB to IIIB epidermoid cervical cancer, no prior therapy, and an Eastern Cooperative Oncology Group performance status of 0 to 2. Patients received erlotinib at a dose of 150 mg/day 1 week before and in combination with cisplatin (40 mg/m2 administered weekly for 5 cycles) and radiotherapy (4500 centigrays in 25 fractions), followed by brachytherapy (4 fractions at a dose of 600 centigrays weekly).RESULTS: A total of 36 patients completed treatment with E + CRT. The median duration of therapy was 77 days and the median follow‐up period was 59.3 months. The therapy was well tolerated overall, and 34 patients (94.4%) achieved a complete response. The 2‐year and 3‐year cumulative overall and progression‐free survival rates were 91.7% and 80.6% and 80% and 73.8%, respectively.CONCLUSIONS: Treatment with E + CRT appears to be safe and exerts significant activity against locally advanced cervical cancer. To the best of the authors' knowledge, this is the first study to date to demonstrate that a target agent has promising activity against locally advanced cervical cancer. Cancer 2014;120:1187–1193. © 2014 American Cancer Society.

1 January 2016 in Oral Oncology
Verified
Journal Article
Closed access
HAHéliton S. Antunes
Héliton S. Antunes
LSLuciene Fontes Schluckebier
Luciene Fontes Schluckebier
DHDaniel Herchenhorn
Daniel Herchenhorn
ISIsabele A. Small
Isabele A. Small
CACarlos M.M. Araújo
Carlos M.M. Araújo
CFCarlos G. Ferreira
Carlos G. Ferreira